EPO and diabetes mellitus: Moreover, McVicar and coworkers [35] have recently demonstrated that treatment with an EPO-derived peptide in fully established diabetes could significantly protect against neuroglia and vascular degenerative pathology without altering hematocrit or exacerbating neovascularization (2011).